Shuttle Pharmaceuticals Holdings, Inc.
SHPHHealthcare|Drug Manufacturers - Specialty & Generic|US
$5.58
+0.55 (+10.81%)
Tangible Book / Share
$10.38
Cash / Share
$0.09
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06359379 Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter | Glioblastoma, IDH-wildtype | P2 | Terminated | 30 | RCT, Open-label | Ropidoxuridine |